Steven M. Fox, CPA

home / authors / steven-m-fox-cpa

Articles

Site Logo

Generational Impact on Prescription Drug Trend: Part 2

Anna A. Theodorou, RPh, MBA;John A. Szychowski, AAS, BS;Julie Slezak, MS;Steven M. Fox, CPA
September 1st 2010

This retrospective study of 558.9 million prescription claims explores how member age demographics affect prescription drug trends and provides top therapeutic classes by generation.

Read More

Site Logo

Generational Impact on Prescription Drug Trend: Part 1

Anna A. Theodorou, RPh, MBA;John A. Szychowski, AAS, BS;Julie Slezak, MS;Steven M. Fox, CPA
July 1st 2009

Part 1 of this 2-part overview of prescription drug trend focuses on important therapeutic classes for all generations.

Read More

Latest Updated Articles

10 Pharmacy Quotes That Will Make You Rethink the Profession
Published: January 18th 2016 | Updated: October 18th 2024
10 Pharmacy Quotes That Will Make You Rethink the Profession
Gabapentin Differs From Pregabalin in Several Key Ways
Published: September 22nd 2015 | Updated: October 14th 2024
Gabapentin Differs From Pregabalin in Several Key Ways
Semaglutide injecting pen on a white background, macro. Needle macro - Image credit: artmim | stock.adobe.com
Published: October 17th 2024 | Updated: October 23rd 2024
Concerns Linger About GLP-1 Agonists Despite Their Popularity
Vial with pneumococcal disease vaccine and syringe for injection.
Published: October 21st 2024 | Updated: October 23rd 2024
Pneumococcal 21-Valent Conjugate Vaccine Generates Positive Response in Adults at Increased Risk of Disease
Myasthenia Gravis disease blood test in doctor hand
Published: October 21st 2024 | Updated: October 23rd 2024
Myasthenia Gravis Negatively Impacts Patients and Care Partners Through Clinical, Financial Burdens
FDA Approval, Stelara, Biosimilar | Image Credit: Calin - stock.adobe.com
Published: October 1st 2024 | Updated: October 23rd 2024
FDA Approves Ustekinumab-Aauz as Biosimilar for Stelara